- Raw materials
- Antibacterials
- Faropenem medoxomil
Faropenem medoxomil API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Faropenem medoxomil | CAS No: 141702-36-5 | GMP-certified suppliers
A medication that targets bacterial infections including bronchitis, otitis media, and pediatric indications, offering broad-spectrum antibacterial activity with enhanced oral bioavailability.
Therapeutic categories
Primary indications
- Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications
Product Snapshot
- Faropenem medoxomil is an oral small molecule antibiotic
- Its primary therapeutic applications include treatment of bacterial infections, bronchitis, otitis media, and pediatric indications
- Currently, faropenem medoxomil remains in an investigational status without FDA or EMA approval
Clinical Overview
Clinically, faropenem medoxomil has been investigated for the treatment of bacterial infections, including bronchitis, otitis media, and certain pediatric infections. It demonstrates potent in vitro activity against common respiratory pathogens, many aerobic gram-positive bacteria, and anaerobes. Its activity against gram-negative organisms tends to be more limited. Preliminary in vivo studies support its efficacy in community-acquired infections such as uncomplicated skin and skin structure infections, although additional clinical data are required to define its precise role in antimicrobial therapy.
The antibacterial effect of faropenem is mediated through inhibition of bacterial cell wall synthesis. It competitively binds to bacterial transpeptidase enzymes, inhibiting the cross-linking of peptidoglycan polymers that are essential for cell wall integrity, particularly in Gram-positive bacteria. This mechanism is typical of beta-lactam antibiotics, conferring bactericidal activity through disruption of cell wall maturation.
Pharmacokinetic parameters emphasize the improved oral absorption of faropenem medoxomil as a prodrug, facilitating systemic exposure sufficient to target susceptible pathogens. Specific ADME data are limited, and further characterization is ongoing.
Safety and toxicity profiles have not been fully established; as an investigational agent, faropenem medoxomil requires continued evaluation to determine its tolerability and risk-benefit balance. There are no globally approved products currently marketed under notable brand names, as development is ongoing through collaborations including Replidyne, Inc., and Forest Laboratories, Inc.
For API procurement, strict adherence to quality control standards including purity, stability, and correct prodrug composition is essential. Documentation verifying compliance with regulatory guidelines for investigational compounds should be maintained to support downstream formulation and clinical applications.
Identification & chemistry
| Generic name | Faropenem medoxomil |
|---|---|
| Molecule type | Small molecule |
| CAS | 141702-36-5 |
| UNII | 5OK523O4FU |
| DrugBank ID | DB05659 |
Pharmacology
| Summary | Faropenem is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, including PBP1A, PBP2B, and peptidoglycan synthase FtsI, thereby preventing cross-linking of peptidoglycan chains. It exhibits broad-spectrum activity against Gram-positive bacteria, common respiratory pathogens, and anaerobes, with more limited activity against Gram-negative organisms. Its pharmacodynamic profile supports investigation for treatment of community-acquired bacterial infections such as bronchitis and otitis media. |
|---|---|
| Mechanism of action | Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis. |
| Pharmacodynamics | Faropenem has demonstrated excellent in vitro activity against common respiratory pathogens, many aerobic gram-positive organisms, and anaerobes. Activity against gram-negative organisms is more reserved. In vivo data suggest that faropenem is efficacious in treating community-acquired infections including uncomplicated skin and skin structure infections; however, more data may help to characterize faropenem's place in antimicrobial therapy. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Penicillin-binding protein 1A | Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | |
| Penicillin-binding protein 2B | Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | |
| Peptidoglycan synthase FtsI | Escherichia coli O157:H7 |
Formulation & handling
- Faropenem medoxomil is a small molecule suitable for oral formulation given its moderate water solubility and low logP value.
- The compound’s alpha amino acid derivative structure suggests potential stability considerations under acidic or enzymatic conditions.
- Handling should account for moisture sensitivity due to its solid state and moderate aqueous solubility.
Regulatory status
Faropenem medoxomil is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
